Nuvectis Pharma, Inc. SEC Filings

Nuvectis Pharma (NVCT) director reported an open-market purchase of 13,000 shares on November 5, 2025 at a weighted average price of $5.79. After the transaction, the director beneficially owned 78,150 shares directly and 415 shares indirectly as custodian for a son. The filing notes the purchase was executed through multiple same-day trades within a price range of $5.77 to $5.81, consolidated as a single line item.

Nuvectis Pharma (NVCT): Director Matthew Kaplan purchased 11,000 shares of common stock on 11/05/2025 in an open‑market transaction coded “P” at a weighted average price of $5.84. Following this trade, he beneficially owns 124,760 shares, held directly.

The filing notes the price was a weighted average across multiple same‑day trades within a $5.81–$5.88 range, and detailed breakdowns are available upon request.

Nuvectis Pharma, Inc. filed an 8‑K to furnish a press release providing a corporate update and financial results for the third quarter ended September 30, 2025. The press release is included as Exhibit 99.1 and, as stated, the information is being furnished and not deemed filed under the Exchange Act.

The company’s common stock trades on the Nasdaq Capital Market under the symbol NVCT. The filing also includes the iXBRL cover page as Exhibit 104.

Nuvectis Pharma (NVCT) reported Q3 2025 results showing higher operating spending as clinical programs progressed and licensing costs increased. Cash and cash equivalents were $35.4 million as of September 30, 2025, compared with $18.5 million at year-end 2024. The company posted a Q3 net loss of $7.5 million and a nine‑month net loss of $19.1 million. A warrant term extension recorded as an $2.4 million effect increased the total net loss attributable to common shareholders in Q3.

Operating drivers: R&D expense rose to $5.8 million in Q3 (from $2.8 million) mainly due to a $2.0 million license fee for NXP900 and higher clinical costs; G&A was $2.0 million (from $1.5 million). Year‑to‑date, R&D reached $13.1 million and G&A $6.9 million. To fund operations, Nuvectis raised capital via equity: in February 2025 it sold 3,105,000 shares at $5.00 for $14.0 million net, and in Q3 it sold 1,707,309 shares under its ATM for $13.5 million gross ($13.1 million net). Management believes current cash funds planned operations for at least 12 months.

Pipeline: NXP900 advanced into Phase 1b in August 2025; a DDI study classified it as a weak CYP3A inhibitor. The company issued a final update for NXP800 in July and will not pursue further development in ovarian cancer while assessing other indications.

Nuvectis Pharma (NVCT) reported a Form 4 for director Juan Sanchez showing the acquisition of 30,000 shares of restricted common stock on 09/22/2025 at a stated price of $0. The award vests in equal annual installments over three years beginning on the first anniversary of the grant date, contingent on his continued service on the Board.

After the reported transaction, Dr. Sanchez beneficially owned 65,150 shares directly and 415 shares indirectly as custodian for his son.

Nuvectis Pharma (NVCT) reported an initial Form 3 for a director with an event date of 09/22/2025. The filing lists beneficial ownership of 35,150 shares of common stock (direct), plus 295 shares (indirect) and 120 shares (indirect) held as custodian for a son. Table II shows no derivative securities. The form was signed by Juan Sanchez on 10/31/2025.

Nuvectis Pharma (NVCT) reported insider purchases by director Charles Mosseri‑Marlio. He indirectly acquired common stock across three open‑market transactions: 46,900 shares at $6.06 on October 23, 35,034 shares at $6.15 on October 24, and 72,836 shares at $6.28 on October 27.

Following these trades, he beneficially owned 3,136,576 shares, held indirectly through Emerald Hill Ventures SARL SPF, of which he is the beneficial owner.